X

Trial Profile

Multisystem Inflammatory Syndrome Therapies in Children (MISTIC) Comparative Effectiveness Study

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 01 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anakinra (Primary) ; Anakinra (Primary) ; Infliximab (Primary) ; Methylprednisolone (Primary) ; Methylprednisolone (Primary)
Indications Cryopyrin-associated periodic syndromes; Multisystem disorders
Focus Therapeutic Use
Acronyms MISTIC

Most Recent Events

27 Sep 2024 Planned End Date changed from 22 Dec 2023 to 31 Jul 2025.
27 Sep 2024 Status changed to active, no longer recruiting.
06 May 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com